DHHealthcare · Health Information ServicesThe 7 Wall Street analysts covering Definitive Healthcare Corp. hold a median 12-month price target of $2.25 — +252.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 13 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Definitive Healthcare Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (7): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +252.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | Morgan Stanley | Maintains | Equal-Weight | $2.50 → $1.50 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | $3.50 → $0.70 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | — |
| 30 Mar 2026 | Barclays | Maintains | Underweight | — |
| 27 Feb 2026 | Canaccord Genuity | Maintains | Hold | — |
| 27 Feb 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 9 Dec 2025 | Barclays | Maintains | Underweight | — |
| 10 Nov 2025 | Canaccord Genuity | Maintains | Hold | — |
| 8 Aug 2025 | Stifel | Maintains | Buy | — |
| 12 May 2025 | Goldman Sachs | Maintains | Neutral | — |
| 4 Mar 2025 | Goldman Sachs | Maintains | Neutral | — |
| 3 Mar 2025 | Barclays | Maintains | Underweight | — |
| 16 Jan 2025 | Needham | Reiterates | Hold | — |
| 13 Jan 2025 | Barclays | Downgrade | Underweight | — |
| 20 Dec 2024 | Stephens & Co. | Initiates | Equal-Weight | — |
| 8 Nov 2024 | Needham | Reiterates | Hold | — |
| 17 Sept 2024 | BTIG | Initiates | Buy | — |
| 9 Aug 2024 | Deutsche Bank | Maintains | Hold | — |
| 7 Aug 2024 | Baird | Maintains | Neutral | — |
| 7 Aug 2024 | Barclays | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DH appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 89% of US stocks
Cheaper than 85% of US stocks
Cheaper than 56% of US stocks
Higher than 16% of US stocks
Higher than 29% of US stocks
Higher than 87% of US stocks
Higher than 25% of US stocks
Higher than 8% of US stocks
Higher than 16% of US stocks
Higher than 37% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Definitive Healthcare Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Definitive Healthcare Corp. (DH) held its Q2 2026 earnings call, and the full transcript of that call has been published by Seeking Alpha. The transcript covers the company's second-quarter fiscal 2026 results discussion.
Why it matters — DH watchers would care because the earnings call transcript provides the full management commentary on the company's Q2 2026 performance and outlook.
Definitive Healthcare Corp. (DH) reported Q2 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.07 per share in the same quarter a year ago.
Why it matters — The earnings beat the analyst consensus estimate, which is a notable data point for those tracking DH's quarterly performance, even though earnings declined year-over-year.
Definitive Healthcare reported second-quarter fiscal 2026 revenue and profitability that met or exceeded its guidance ranges. Management highlighted improving retention trends and continued investment in artificial intelligence products as part of its plan to return to growth.
Why it matters — The results and management's stated focus on retention and AI investment signal the company's strategy toward returning to growth, which is relevant for DH watchers.
Definitive Healthcare announced the launch of an Early Adopter Program for its new AI-powered healthcare intelligence platform. The platform reportedly unifies claims, provider, consumer, and expert data to help organizations uncover growth opportunities and make faster, better-informed decisions.
Why it matters — The launch signals a potential product expansion for Definitive Healthcare, which DH watchers would monitor as a development in its platform offerings.
Definitive Healthcare Corp. announced it will report its second quarter 2026 financial results on Monday, August 10, 2026, after market close. The company will host a conference call and webcast at 5:00 PM ET/2:00 PM PT to discuss the results.
Why it matters — The announcement lets DH watchers know when the company's second quarter results and management commentary will be available.
The 7 Wall Street analysts covering Definitive Healthcare Corp. have a median 12-month price target of $2.25, with estimates ranging from $0.7 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Definitive Healthcare Corp., 1 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Definitive Healthcare Corp. 82 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Aug 2026, Definitive Healthcare Corp. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +252.0% from the last close, and Ticker Nerd's factor model ranks Definitive Healthcare Corp. 82 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Definitive Healthcare Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.7 to $3 over the next 12 months.
Definitive Healthcare Corp. returned -83.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Definitive Healthcare Corp provides healthcare commercial intelligence through a cloud-based, subscription-based software platform designed for life sciences companies, healthcare providers, payers, and consulting firms. The platform aggregates data from multiple sources—including claims data, government registries, commercial filings, and proprietary research—to deliver comprehensive insights on the healthcare ecosystem.
The most recent item we track (Seeking Alpha, 11 Aug 2026): "Definitive Healthcare Corp. (DH) Q2 2026 Earnings Call Transcript". Definitive Healthcare Corp. (DH) held its Q2 2026 earnings call, and the full transcript of that call has been published by Seeking Alpha. The transcript covers the company's second-quarter fiscal 2026 results discussion.
Definitive Healthcare Corp provides healthcare commercial intelligence through a cloud-based, subscription-based software platform designed for life sciences companies, healthcare providers, payers, and consulting firms. The platform aggregates data from multiple sources—including claims data, government registries, commercial filings, and proprietary research—to deliver comprehensive insights on the healthcare ecosystem. Users leverage the platform to identify market opportunities, optimize sales and marketing strategies, improve operational efficiency, and support clinical research initiatives. The company's flagship offering features detailed profiles on physicians, hospitals, health systems, and post-acute care facilities, enabling customers to make data-driven strategic decisions across product development, go-to-market planning, and physician network management. Founded in 2011 and headquartered in Framingham, Massachusetts, Definitive Healthcare operates primarily in the United States market and serves as a vital intelligence provider across the healthcare sector.
CEO Mr. Kevin D. Coop · 678 employees · United States · https://www.definitivehc.com